Efficacy, tolerability and management of raltitrexed (Tomudex™) monotherapy in patients with advanced colorectal cancer: A review of phase II/III trials

European Journal of Cancer

Volumn 38, Issue 4, 2002, Pages 478-486

  Cunningham, D ^a   Zalcberg, J ^b   Maroun, J ^c   James, R ^d   Clarke, S ^e   Maughan, T S ^f   Vincent, M ^g   Schulz, J ^h   Gonzalez Baron M ⁱ   Facchini, T ^j  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d Kent Cancer Centre   (United Kingdom)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f VELINDRE CANCER CENTRE   (United Kingdom)

^g LONDON REGIONAL CANCER PROGRAM   (Canada)

^h Virginia Oncology Associates   (United States)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j GINECO and Polyclinique Courlancy   (France)

more..

Author keywords

Creatinine clearance; Raltitrexed; Tolerability; Toxicity

Indexed keywords

FLUOROURACIL; FOLINIC ACID; RALTITREXED;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CREATININE CLEARANCE; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; MONOTHERAPY; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 0036186018     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00413-0     Document Type: Article

References (24)

1. ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer
2. Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694)
3. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients
4. Clinical pharmacology of 5-fluorouracil
5. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors
6. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer
7. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
8. Raltitrexed (Tomudex®) versus 5-fluorouracil and leucovorin (5-FU+LV) in patients with advanced colorectal cancer (ACC): Results of a randomized, multicenter, North American trial
9. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
10. A phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors
11. Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimen in the palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CRO6
12. High-dose raltitrexed ('Tomudex') has a manageable toxicity profile in patients with advanced colorectal cancer
13. 2 as second- and third-line therapy in patients with metastatic colorectal cancer
14. Raltitrexed ('Tomudex') has a manageable toxicity profile in elderly patients with metastatic colorectal cancer: Final analysis of a multicentre study
15. 'Tomudex' (raltitrexed) in elderly patients with advanced colorectal cancer (ACC): An effective palliative treatment
16. Which 5-fluorouracil regimen? - The great debate
17. Phase I study of raltitrexed [ZD-1694]
18. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number
19. Overview of the tolerability of 'Tomudex' (raltitrexed): Collective clinical experience in advanced colorectal cancer
20. Prediction of creatinine clearance from serum creatinine
21. Leucovorin rescue from raltitrexed ('Tomudex') induced antiproliferative effects: In vitro cell line and in vivo mouse studies
22. Optimising the side effects of raltitrexed with appropriate supportive drugs. A prospective community hospital study
23. A phase II study of raltitrexed ('Tomudex') combined with carmofur in metastatic CRC